CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Collateral Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Collateral Therapeutics, Inc.
2600 Hilltop Dr
Phone: (302) 636-5400p:302 636-5400 RICHMOND, CA  94806-1971  United States Fax: (302) 636-5454f:302 636-5454
This company is no longer actively traded on any major stock exchange.
Business Summary
Collateral Therapeutics, Inc. is a United States-based company, which is focused on the discovery and development of non-surgical gene therapy products for the treatment of cardiovascular diseases, including coronary artery disease, peripheral vascular disease, congestive heart failure and heart attack. The Company's gene therapy products are designed to promote and enhance angiogenesis, a natural biological process that results in the growth of additional blood vessels to increase levels of blood flow to oxygen-deprived tissues. In collaboration with its partner Schering AG, the Company began early stage testing in humans for Generx, for the gene therapy product candidates. Generx uses a fibroblast growth factor gene, known as FGF-4, to promote and enhance angiogenesis for the treatment of coronary artery disease in patients with stable exertional angina. The Company has also assembled a portfolio of therapeutic genes for use in its potential gene therapy products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/200212/31/2001YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Vice President, Business Development Cleland C.Landolt

Subsidiaries
Business Name Address City State/Province Country
Five Corners Funding Trust II DE United States

Business Names
Business Name
CLTX
Five Corners Funding Trust II

General Information
Number of Employees: 70 (As of 12/31/2001)
Outstanding Shares: 13,369,597 (As of 3/31/2002)
Shareholders: 3,939
Stock Exchange: NASD
Federal Tax Id: 330661290
Fax Number: (302) 636-5454
Email Address: info@collateralthx.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023